Sonia Partap, MD
Neurology With Special Qualifications in Child Neurology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Partap’s office at (650) 497-8000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A95405 · Current
Licensed to practise in California · since 2006 · expires 2028-05-31 · University of Missouri-Kansas City School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$1,987 in 2024
Medicaid paid $1,987 for 13 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 13 | $1,987 |
| 2024 | 13 | 1 | 12 | $1,987 |
| 2023 | 166 | 2 | 18 | $21,349 |
| 2022 | 93 | 1 | 16 | $12,776 |
| 2021 | 114 | 1 | 20 | $15,797 |
| 2020 | 94 | 2 | 16 | $11,352 |
| 2019 | 105 | 2 | 23 | $10,995 |
| 2018 | 92 | 1 | 15 | $9,524 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 140 | $18,932 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 26 | $2,417 |
2022
| Long return visit (40+ min) | 93 | $12,776 |
2021
| Long return visit (40+ min) | 114 | $15,797 |
2020
| Long return visit (40+ min) | 76 | $9,704 |
| Return visit (30+ min) | 18 | $1,647 |
2019
| Long return visit (40+ min) | 77 | $9,231 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 28 | $1,764 |
2018
| Long return visit (40+ min) | 92 | $9,524 |
Money from drug and device companies
$358 in 2025
| 2025 | 3 | 4 | None | $358 |
| 2022 | 1 | 1 | $1,042 | $1,042 |
| 2021 | 1 | 1 | $1,217 | $1,217 |
| 2020 | 1 | 2 | $1,365 | $1,365 |
| 2019 | 2 | 6 | $900 | $2,184 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Day One Biopharmaceuticals | Ojemda | $141 | 2 payments
|
| HEMA Biologics | Iwilfin | $116 | 1 payment
|
| Jazz Pharmaceuticals | Modeyso | $101 | 1 payment
|
See all 4 published payments
| Jazz Pharmaceuticals | Meals · 2025-11-18 | Modeyso | $101 |
| HEMA Biologics | Meals · 2025-10-29 | Iwilfin | $116 |
| Day One Biopharmaceuticals | Meals · 2025-09-18 | Ojemda | $22 |
| Day One Biopharmaceuticals | Meals · 2025-07-31 | Ojemda | $119 |
See earlier years (2022, 2021, 2020, 2019)
2022: $1,042
| Biogen | None | $1,042 | 1 payment
|
2021: $1,217
| Biogen | None | $1,217 | 1 payment
|
2020: $1,365
| Biogen | None | $1,365 | 2 payments
|
2019: $2,184
| Celgene | Pomalyst | $1,284 | 5 payments
|
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $900 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Celgene Corporation · Phase 2 Clinical Study of Pomalidomide (Cc-4047) Monotherapy for Children and Young Adults With Recurrent Or Progressive Primary Brain Tumors (Cc-4047-Brn-001) · 2019 | Their institution | $49,371 |
| Eli Lilly and Company · A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared To Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy · 2025 | Their institution | $28,811 |
| Day One Biopharmaceuticals · Loggic/Firefly-2: A Phase 3, Randomized, International Multicenter Trial of Day101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring An Activating Raf Alteration Requiring First-Line Systemic Therapy · 2025 | Their institution | $21,142 |
| Genentech, Inc. · Phase I II Open Label Study Evaluating Safety Pharmacokinetics and Efficacy of Alectinib in Pedia · 2024 | Their institution | $18,383 |
| AbbVie, Inc. · 2019 | Their institution | $11,907 |
| Celgene Corporation · Phase 2 Clinical Study of Pomalidomide (Cc-4047) Monotherapy for Children and Young Adults With Recurrent Or Progressive Primary Brain Tumors · 2020 | Their institution | $11,048 |
| Genentech, Inc. · Phase I II Open Label Study Evaluating Safety Pharmacokinetics and Efficacy of Alectinib in Pedia · 2025 | Their institution | $3,840 |
| Eli Lilly and Company · A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared To Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy · 2024 | Their institution | $611 |
Professional record
- NPI
- 1104032648
- Licence
- CA A95405California A95405: Current · expires 2028-05-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0402X (2084N0402X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2007-05-14
- NPI last updated
- 2023-11-10
- NPI record certified
- 2023-11-10
This is when the NPI record was last certified, not a medical board exam.